Ind-Swift Limited's latest marketcap:
As of 07/05/2025, Ind-Swift Limited's market capitalization has reached $10.9 M. According to our data, Ind-Swift Limited is the 39946th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 10.9 M |
| Revenue (ttm) | 60.31 M |
| Net Income (ttm) | 33.18 M |
| Shares Out | 0 |
| EPS (ttm) | 0.61 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 06/25/2025 |
Ind-Swift Limited's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | ₹10.9 M | -48.98% | 39946 |
| 12/31/2024 | ₹1.78 B | 83.72% | 33935 |
| 12/29/2023 | ₹968.46 M | 41.12% | 36430 |
| 12/30/2022 | ₹686.27 M | -0.39% | 36630 |
| 12/31/2021 | ₹688.97 M | 218% | 35796 |
| 12/28/2020 | ₹216.66 M | 23.46% | 34855 |
| 12/31/2019 | ₹175.49 M | -53.04% | 32094 |
| 12/31/2018 | ₹373.74 M | -39.21% | 29530 |
| 12/29/2017 | ₹614.77 M | 110.53% | 27730 |
| 12/29/2016 | ₹292.01 M | -1.86% | 27111 |
Company Profile
About Ind-Swift Limited
Ind-Swift Limited is a leading pharmaceutical company based in Chandigarh, India, specializing in the development and manufacturing of a wide range of healthcare products. Established in 1983, the company operates in multiple therapeutic segments, offering high-quality medicines and formulations.
Core Offerings
- Pharmaceutical Formulations: Finished dosage forms, active pharmaceutical ingredients (APIs), and herbal products.
- Therapeutic Segments: ENT, dentistry, anti-infectives, cardio-diabetic, orthopedics, gynaecology, pediatrics, dermatology, and more.
- Popular Brands: Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, Stemin Forte, Anin, Suprox, Cozy, Distone, and Oliade.
- Ayurvedic Products: A range of herbal and traditional medicines.
- Contract Research & Manufacturing: Services for third-party pharmaceutical development.
Global Reach
Ind-Swift exports its products to key international markets, including Europe, Australia, Canada, South Africa, and Russia. The company also licenses its products to global partners.
Therapeutic Applications
- Antibiotics & Anti-infectives
- Anti-cold & Anti-allergic
- Nutraceuticals & Anti-diarrhoeal
- Anti-malarial & Anti-depressants
- Cardiology & Diabetology
- Neurology & Oncology
With decades of expertise, Ind-Swift Limited continues to innovate and expand its presence in the pharmaceutical industry, delivering trusted healthcare solutions worldwide.
Frequently Asked Questions
-
What is Ind-Swift Limited's (NSE-INDSWFTLTD) current market cap?As of 07/05/2025, Ind-Swift Limited (including the parent company, if applicable) has an estimated market capitalization of $10.9 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Ind-Swift Limited (NSE-INDSWFTLTD) rank globally by market cap?Ind-Swift Limited global market capitalization ranking is approximately 39946 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.